Resolved to apply a restricted stock compensation plan through issuance of new shares. 17,700 shares to be issued at an issue price of 7,550 yen, total amount 133,635,000 yen, allocated to employees and directors. Restriction periods up to 5 years; detailed conditions for lifting restrictions upon expiration are specified.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"Oncolys BioPharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4588-20261106-03.pdf","jir_short_summary":"Resolved to apply a restricted stock compensation plan through issuance of new shares. 17,700 shares to be issued at an issue price of 7,550 yen, total amount 133,635,000 yen, allocated to employees and directors. Restriction periods up to 5 years; detailed conditions for lifting restrictions upon expiration are specified.","jir_summary":"### Overview\nAt today's board meeting, the board resolved to issue new shares as restricted stock compensation. The shares to be issued are 17,700 ordinary shares, the issue price is 7,550 yen per share, and the total amount is 133,635,000 yen. Allocations will be made to three internal directors and 20 employees, and payment will be made on the premise of concluding restricted stock allocation agreements specifying the terms. The restriction periods are set based on 2026\/11\/24\u20132028\/11\/30 (example for internal directors) and for employees similarly based on 2026\/11\/24\u20132028\/11\/30.\n\n### Impact on Shareholders and Future Outlook\nThe purpose of the stock compensation plan is to strengthen incentives to contribute to share price appreciation and corporate value enhancement. During the restriction period, disposition such as transfer of the shares is restricted, and restrictions will be lifted if conditions are met at the time of expiration. Special conditions for corporate reorganizations and the like are also stipulated, aiming to motivate performance-linked behavior through long-term incentive design.","jir_financial_highlights":"Number of shares to be issued: 17,700 shares (Unknown)\nTotal issue amount: 133,635,000 yen (Unknown)\nIssue price: 7,550 yen (Unknown)","jir_category":"","jir_hashtags":"#OncolysBioPharma, #StockOption","jir_key_figures":"Key figure 1: Number of shares to be issued 17,700 shares\nKey figure 2: Total issue amount 133,635,000 yen\nKey figure 3: Issue price 7,550 yen","jir_meta_title":"Oncolys BioPharma Inc. Decides on Issuance of New Shares as Restricted Stock Compensation\uff5cNovember 2026","jir_meta_description":"Oncolys BioPharma Inc. resolved to issue new shares as restricted stock compensation. Details provided on number of shares, issue price, total amount, allocation recipients, restriction periods, and conditions for lifting restrictions. Explains long-term incentive design aimed at enhancing shareholder value.","jir_og_title":"Oncolys BioPharma: Decision to Issue New Shares as Restricted Stock Compensation","jir_og_description":"Resolved to issue new shares as restricted stock compensation. 17,700 shares to be issued, total amount 133,635,000 yen, restriction period up to 5 years. Details of long-term incentives aimed at enhancing shareholder value.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-144034","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n